Orchestra BioMed Holdings (OBIO) Amortization of Deferred Charges (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $64000.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges changed N/A to $64000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $215000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $215000.0 for FY2025, 593.55% up from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $64000.0 at Orchestra BioMed Holdings, up from $59000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $64000.0 in Q4 2025, with the low at $3000.0 in Q4 2023.
  • Average Amortization of Deferred Charges over 3 years is $40833.3, with a median of $36500.0 recorded in 2022.
  • Peak annual rise in Amortization of Deferred Charges hit 2.78% in 2023, while the deepest fall reached 91.67% in 2023.
  • Over 3 years, Amortization of Deferred Charges stood at $36000.0 in 2022, then tumbled by 91.67% to $3000.0 in 2023, then skyrocketed by 2033.33% to $64000.0 in 2025.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods came in at $64000.0, $59000.0, and $46000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.